Search - tctmd.com

Displaying 721 - 740 of 1148

Sort: Relevancy | Date

News Industry News

InspireMD to Showcase Embolic Systems with MicroNetTM Technology and Results from MASTER I Trial at EuroPCR Conference

May 20, 2014

News Conference News EuroPCR 2014

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Caitlin E. Cox

May 20, 2014

News Conference News EuroPCR 2014

APPOSITION IV: Self-Expanding SES Covers Struts Better, Faster than Balloon-Expandable DES

Yael L. Maxwell

May 20, 2014

News Daily News

CABG Achieves Better 30-Day Outcomes vs PCI in Younger Patients, Similar 5-year Mortality

Yael L. Maxwell

May 15, 2014

News Industry News

Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System

May 13, 2014

News Industry News

CRF will Provide Updates on Several Key Cardiovascular Trials at EuroPCR

May 13, 2014

News Industry News

Tryton Medical Announces Events at EuroPCR 2014 in Paris

May 12, 2014

News Industry News

Biosensors Announces IDE Approval for BioFreedom™ U.S. Trial

May 05, 2014

News Daily News

Bivalirudin Safer Than Heparin Alone in ‘Real-World’ PCI Patients Without STEMI

Yael L. Maxwell

May 01, 2014

News Daily News

Long-term Outcomes of ‘Full Metal Jacket’ Stenting Appear Favorable

April 30, 2014

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

News Daily News

Cardiac Rehab Reduces Late Lumen Loss, Improves Risk Profile in Patients with Long Lesions

April 14, 2014

Presentation Fellows 2014

Drug-Eluting Stents: Past, Present, and Future

Presenter: Gregg Stone

April 12, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

Presentation ACC 2014

Two-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Presenter: Masahiro Natsuaki

March 31, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Conference News ACC 2014

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Jason Kahn

March 31, 2014

News Daily News

DES Outcomes Vary by Diabetes Status, Lesion Complexity

Caitlin E. Cox

March 13, 2014

News Industry News

Boston Scientific Receives CE Mark Approval for REBEL™ Platinum Chromium Coronary Stent System

March 12, 2014

News Industry News

Abbott Completes Enrollment of Absorb™ Randomized Clinical Trials in the United States, Japan and China

March 10, 2014

Advertisement

InspireMD to Showcase Embolic Systems with MicroNetTM Technology and Results from MASTER I Trial at EuroPCR Conference

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

APPOSITION IV: Self-Expanding SES Covers Struts Better, Faster than Balloon-Expandable DES

CABG Achieves Better 30-Day Outcomes vs PCI in Younger Patients, Similar 5-year Mortality

Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System

CRF will Provide Updates on Several Key Cardiovascular Trials at EuroPCR

Tryton Medical Announces Events at EuroPCR 2014 in Paris

Biosensors Announces IDE Approval for BioFreedom™ U.S. Trial

Bivalirudin Safer Than Heparin Alone in ‘Real-World’ PCI Patients Without STEMI

Long-term Outcomes of ‘Full Metal Jacket’ Stenting Appear Favorable

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

Cardiac Rehab Reduces Late Lumen Loss, Improves Risk Profile in Patients with Long Lesions

Drug-Eluting Stents: Past, Present, and Future

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

Two-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

DES Outcomes Vary by Diabetes Status, Lesion Complexity

Boston Scientific Receives CE Mark Approval for REBEL™ Platinum Chromium Coronary Stent System

Abbott Completes Enrollment of Absorb™ Randomized Clinical Trials in the United States, Japan and China

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content